CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrog
| Revenue (Most Recent Fiscal Year) | $43.47M |
| Net Income (Most Recent Fiscal Year) | $-17.93M |
| PE Ratio (Current Year Earnings Estimate) | 12.28 |
| PE Ratio (Trailing 12 Months) | 53.59 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 9.69 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.96 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 20.81% |
| Net Margin (Trailing 12 Months) | 20.81% |
| Return on Equity (Trailing 12 Months) | 22.57% |
| Return on Assets (Trailing 12 Months) | 17.02% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.21 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.99 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.62 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.40 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.30 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.30 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.22 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 67.82M |
| Free Float | 64.23M |
| Market Capitalization | $799.65M |
| Average Volume (Last 20 Days) | 2.44M |
| Beta (Past 60 Months) | 1.58 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 34.18% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |